Penumbra Inc. stock reached a new 52-week high, closing at $328.69, marking a significant milestone for the medical device company. The $12.93 billion market cap company trades at a P/E ratio of 75.62, and according to InvestingPro analysis, the stock appears overvalued relative to its Fair Value—placing it among considerations for the most overvalued stocks list. Over the past year, Penumbra’s stock has experienced a robust increase, with a 22.34% rise in its share price. This upward trajectory highlights investor confidence and the company’s strong performance in the healthcare sector, supported by impressive 17.27% revenue growth and a 67.38% gross profit margin in the last twelve months. The new high underscores Penumbra’s growth potential, driven by its innovative product offerings and strategic market expansion. InvestingPro subscribers can access a comprehensive Pro Research Report on Penumbra, one of 1,400+ US equities covered, along with 14 additional ProTips to guide investment decisions. As the stock continues to climb, market analysts are closely monitoring its performance for future investment opportunities.
In other recent news, Penumbra, Inc. reported fourth-quarter 2025 revenue of $385.4 million, surpassing Street estimates of $367.7 million. The company’s adjusted EBITDA reached $79.1 million, exceeding expectations of $66.7 million. Penumbra’s shareholders have also approved a merger with Boston Scientific Corporation, with a significant majority voting in favor of the Agreement and Plan of Merger. In clinical developments, Penumbra presented promising results from the STORM-PE trial, showing improved outcomes for patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy.
Analyst firms have weighed in on these developments, with UBS maintaining a Neutral rating on Penumbra’s stock and setting a price target of $374.00. Meanwhile, Evercore ISI raised its price target for Penumbra shares to $360, citing growth in embolization despite U.S. thrombectomy results missing estimates. The analyst from Evercore ISI noted that the challenging comparisons in U.S. venous thromboembolism growth contributed to the shortfall. These recent developments reflect a dynamic period for Penumbra, capturing attention from both investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.